Page 2 - Sanket Koul

Medanta Hospitals Q2 results: Net profit rises 4.5% to Rs 130 crore

The company's ARPOB per day rose to Rs 62,140 in Q2 FY25, a marginal growth of 1.9 per cent Y-o-Y compared to Rs 61,003 reported for the same period last year

India's import dependence on key pharma ingredients may reduce by half

Two newly inaugurated units will manufacture important molecules used in several common antibiotics

Zydus Lifesciences net profit up 14% on strong India, US formulations biz

The growth is attributed to strong performances across domestic and international formulations, and double-digit growth in the consumer wellness business

Indian pharmaceutical market registers over 6% growth in October 2024

The value growth comes at a time when the IPM has registered a negative volume growth of 1.8 per cent

Govt launches Rs 500 crore scheme to strengthen medical devices industry

This initial outlay of Rs 500 crore will be for three years, up to financial year 2026-27 (FY27), according to a government communication

Fortis Healthcare Q2 profit up 5%, revenue rises 12% on strong hospital biz

The company's revenue from operations rose to Rs 1,988 crore in Q2 FY25, a 12.3 per cent Y-o-Y increase from Rs 1,770 crore reported in Q2 FY24

Yatharth Hospitals Q2FY25 results: Net profit up 12%, revenue rises 27%

The growth is attributed to higher occupancy rates and an increase in revenue per bed during the September quarter

New launches likely to fuel domestic growth: JB Pharma CEO Nikhil Chopra

JB Pharma is on track to deliver strong results in the second half of financial year 2024-25

Cabinet approves PM-Vidyalaxmi to provide aid to meritorious students

Rs 3,600 crore outlay outlined for the scheme till FY31

Medanta signs O&M pact for 750 bed hospital in Delhi, to invest Rs 600 cr

"The hospital is expected to commence operations in around four years, subject to necessary statutory and customary approvals"

JB Pharma Q2: PAT up 16%, revenue rises 13% over strong domestic growth

The company stated it has a strong order book for the remaining quarters of this financial year

Max Healthcare Q2: Net profit up 1.9% at Rs 281.81 cr, revenue rises 25%

Hospital chain's average revenue per occupied bed increases 2% at Rs 76,100

Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics CEO & MD

Shreehas Tambe, MD & CEO, Biocon Biologics talks about refinancing, upcoming launches, and future roadmap, in a virtual interaction

Mankind Pharma Q2 results: PAT rises 29% to Rs 659 crore, revenue up 14%

Mankind's revenue from operations rose to Rs 3,077 crore in Q2 FY25, a 13.6 per cent Y-o-Y rise from Rs 2,708 crore reported in Q2 FY24

Lifestyle changes, lack of screening behind rise in breast cancer cases

The data also suggests that states such as Uttar Pradesh, Maharashtra, and West Bengal had the highest incidences of breast cancer in 2023

Ayushman Bharat expansion to benefit elderly; experts raise key concerns

With rising number of patients, healthcare providers call for timely payments

PM Narendra Modi rolls out health cover for 70-plus senior citizens

Beneficiary base expansion to be done at an outlay of Rs 3,437 crore

Medical device makers claim import of refurbished devices can harm industry

Manufacturing associations added that recent government orders permitting such imports threaten the efforts of Indian manufacturers to meet the vision of Aatmanirbhar Bharat

Torrent Pharma Q2FY25 results: Net profit rises 17%, misses estimates

At an operational level, Torrent Pharma's earnings before interest, tax, depreciation, and amortisation stood at Rs 939 crore, with an Ebitda margin of 32.5 per cent

CDSCO flags 4 drugs as spurious and 48 as not of standard quality

The apex drug regulatory body also listed 48 drugs and formulations, manufactured by 40 companies, as not of standard quality (NSQ)